TZYM Share Price

Open 0.49 Change Price %
High 0.50 1 Day -0.03 -5.88
Low 0.47 1 Week 0.00 0.00
Close 0.48 1 Month 0.00 0.00
Volume 126657 1 Year 0.00 0.00
52 Week High 13.27
52 Week Low 7.43
TZYM Important Levels
Resistance 2 0.51
Resistance 1 0.50
Pivot 0.48
Support 1 0.46
Support 2 0.45
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Tranzyme, Inc. (NASDAQ: TZYM)

TZYM Technical Analysis 4
As on 15th Jul 2013 TZYM Share Price closed @ 0.48 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.69 & Sell for SHORT-TERM with Stoploss of 0.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
TZYM Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TZYM Other Details
Segment EQ
Market Capital 102637984.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TZYM Address
TZYM
N/A
Interactive Technical Analysis Chart Tranzyme, Inc. ( TZYM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tranzyme, Inc.
TZYM Business Profile
Ocera Therapeutics, Inc., formerly Tranzyme, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. The Company is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment is complete in a multinational Phase-IIb trial evaluating TZP-102 given once daily in diabetic patients with gastroparesis. The Company has initiated a second Phase-IIb trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis. On July 15, 2013, Ocera Therapeutics, Inc. merged with the Company.